Published in In Vivo, September 2017
Author: Oded Ben-Joseph, Ph.D.
Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters, but the cognitive biases inherent in subjective assessments can derail deals. Executives need to take emotion out of the equation and rely on relevant data to craft successful transactions.
Mergers and acquisition transactions play a central role in the life sciences sector and are the catalyst for growth and transformation, driving innovation from the laboratory all the way to the patient. Life sciences companies often fall victim to recurring misconceptions that lead to unnecessary failure.
– Advisory Services Practice to Assist Growth-Stage Life Science Companies in Pre-Transaction Preparation and Strategic Corporate Development – August 24, 2022 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life science and healthcare investment banking group, today announced the formal launch of an Advisory Services Practice in response to demand from client […]Read More
Outcome Capital Life Science Market Pulse October 2022 Click to view our LifeSciences Pulse NewsletterDownload